Thyroid cancers (TCs) are the most common tumors of the endocrine system and a constant
rise in the number of TC cases has been observed for the past few decades. TCs are one of …

Background: Patients who have metastatic differentiated thyroid cancer (mDTC) frequently
have negative diagnostic and/or post-therapy radioiodine scans. As a result, 131I therapy is …

Editor's note: SNMMI and the European Association of Nuclear Medicine periodically define
new standards/guidelines for nuclear medicine practice to help advance the science of …

Two-thirds of differentiated thyroid cancer (DTC) patients with distant metastases would be
classified as radioactive iodine-refractory (RAIR-DTC), evolving into a poor outcome. Recent …

Thyroid cancer is one of the most common endocrine malignancies. Differentiated thyroid
cancer (DTC) treatment is based on the ability of thyroid follicular cells to accumulate …

Purpose: Lenvatinib has shown efficacy in treating radioiodine-refractory differentiated
thyroid cancer (RR-DTC) in the multinational phase III SELECT study; however, it has not …

Curcumin, a polyphenolic compound, is a well-known anticancer agent, although its poor
bioavailability remains a big concern. Recent studies suggest that autophagy-targeted …

Astatine (211At) is an alpha-emitter with a better treatment efficacy against differentiated
thyroid cancer compared with iodine (131I), a conventional beta-emitter. However, its …

Poorly differentiated thyroid carcinoma (PDTC) is a rare thyroid carcinoma originating from
follicular epithelial cells. No explicit consensus can be achieved to date due to sparse …

Derived from follicular epithelial cells, differentiated thyroid cancer (DTC) accounts for the
majority of thyroid malignancies. The threefold increase in DTC incidence over the last three …